Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224406 | 0.81 | ESR1 (0.38) | ESR1ESR2L3MBTL1ALDH1A1MAPT | |
| SCHEMBL3916038 | 0.81 | ESR1 (0.41) | ESR1ESR2L3MBTL1ALDH1A1MAPT | |
| SCHEMBL22828115 | 0.80 | SMN1; SMN2 (0.39) | ESR1ESR2L3MBTL1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL11011881 | 0.80 | ESR1 (0.37) | ESR1ESR2L3MBTL1ALDH1A1MAPT | |
| SCHEMBL6223628 | 0.79 | TAAR1 (0.43) | ESR1ESR2MAPK1 | |
| SCHEMBL14621143 | 0.79 | ESR1 (0.41) | ESR1ESR2S1PR1S1PR3APLNR | |
| SCHEMBL6223011 | 0.77 | L3MBTL1 (0.40) | ESR1ESR2L3MBTL1ALDH1A1MAPT | |
| SCHEMBL6704226 | 0.75 | CA2 (0.41) | ESR1ESR2 | |
| SCHEMBL20236061 | 0.71 | GBA1 (0.37) | ALDH1A1MAPTS1PR3 | |
| SCHEMBL16385775 | 0.71 | KDM1A (0.43) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547700-B2 | Aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2009-06-16 | — | — | US | disclosed |
| EP-1539738-B1 | NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL -PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PF MEDICAMENT (FR) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100244-A1 | Novel aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2006-05-11 | — | — | US | disclosed |
| EP-1539738-A1 | NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2005-06-15 | — | — | EP | disclosed |
| WO-2003106449-A1 | NOVEL ARYL-{4-HALO-4-[HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL}-METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100244-A1 | Novel aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | CYP4B1, CYP4X1, CYP2E1 | ESR1 3169/4885ESR2 2660/4885L3MBTL1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.